Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K
Disorders of Hemostasis01:24

Disorders of Hemostasis

740
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
740
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

923
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
923
Coagulation01:09

Coagulation

5.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.6K
Autoimmune Disorders01:29

Autoimmune Disorders

396
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibodies in Autoimmune Coagulation Factor Deficiencies: A Review of Inhibitory and Clearance-Accelerating Mechanisms from Japanese Practice.

Seminars in thrombosis and hemostasis·2025
Same author

A case of autoimmune factor XIII deficiency due to clearance-accelerating and inhibitory anti-FXIII autoantibodies.

International journal of hematology·2024
Same author

Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan.

International journal of hematology·2024
Same author

Retrospectively diagnosed autoimmune VWF deficiency in a patient with repeated hemorrhagic events after two common colds.

International journal of hematology·2024
Same author

Clinical features and laboratory diagnostic issues of non-immune, non-amyloid related acquired factor X deficiency.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same author

Novel Immunochromatographic Test for Anti-factor XIII B Subunit Autoantibodies to Diagnose Autoimmune Acquired Factor XIII Deficiency.

Thrombosis and haemostasis·2023

Related Experiment Video

Updated: Jun 14, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K

Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency.

Akitada Ichinose1,2

  • 1Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.

Seminars in Thrombosis and Hemostasis
|June 12, 2025
PubMed
Summary

Autoimmune FXIII deficiency (AiF13D) causes severe bleeding due to autoantibodies. Differentiating AiF13D from non-immune FXIII deficiency (NiF13D) is crucial for appropriate treatment and improved patient outcomes.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.1K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K

Related Experiment Videos

Last Updated: Jun 14, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

18.9K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.1K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.3K

Area of Science:

  • Hematology
  • Immunology
  • Biochemistry

Background:

  • Coagulation factor XIII (FXIII) is vital for hemostatic plug stabilization and dissolution.
  • FXIII deficiency, genetic or acquired, leads to bleeding disorders.
  • Autoimmune FXIII deficiency (AiF13D) presents with severe bleeding due to autoantibodies and accelerated FXIII clearance.

Purpose of the Study:

  • To highlight the critical differences between AiF13D and non-immune FXIII deficiency (NiF13D).
  • To emphasize the diagnostic criteria and therapeutic strategies for AiF13D.
  • To underscore the importance of early diagnosis and long-term management of AiF13D.

Main Methods:

  • Detection of FXIII inhibitors using FXIII activity assays in mixed plasma.
  • Identification of anti-FXIII autoantibodies via immunological assays (often in research settings).
  • Clinical assessment of bleeding symptoms and patient history.

Main Results:

  • AiF13D is characterized by severe FXIII deficiency and high hemorrhagic mortality.
  • FXIII inhibitors and anti-FXIII autoantibodies are key diagnostic markers for AiF13D.
  • NiF13D, often linked to liver cirrhosis or leukemia, has distinct diagnostic and treatment pathways.

Conclusions:

  • Accurate differentiation between AiF13D and NiF13D is essential for effective treatment.
  • AiF13D management requires immunosuppression alongside hemostatic therapy.
  • Long-term follow-up is recommended due to potential treatment resistance in AiF13D.